Core Viewpoint - The announcement of HPV vaccines being included in the national immunization program is expected to positively impact the HPV vaccine market and related companies, which have been struggling with declining performance [1][3][4]. Group 1: Market Response - On September 11, HPV vaccine concept stocks in the A-share market saw a rise, with notable increases in companies such as Kangla Weishi (up 3.09%), Wantai Biological Pharmacy (up 2.69%), Zhifei Biological Products (up 1.98%), and Watson Bio (up 1.71%) [1]. - The National Health Commission's announcement regarding the introduction of HPV vaccination services for eligible girls and its inclusion in the national immunization plan is a significant development [1][2]. Group 2: Industry Challenges - HPV vaccine manufacturers are currently facing challenges due to declining sales and increased competition in the market, leading to a price war [3][4]. - The performance of HPV vaccine companies has been poor, with Wantai Biological reporting a revenue of 844 million yuan, down 38.25% year-on-year, and a net loss of 144 million yuan [4]. - Watson Bio's revenue was 1.154 billion yuan, down 19.47%, with a net profit decline of 74.69% [4]. - Zhifei Biological reported a revenue of 4.919 billion yuan, down 73.06%, and a net loss of 597 million yuan, a 126.72% decline [4][5]. Group 3: Potential for Growth - The global incidence of cervical cancer is rising, particularly among younger women in China, highlighting the need for effective HPV vaccination [6]. - The World Health Organization recommends that countries include HPV vaccination in their national immunization programs, prioritizing girls aged 9 to 14 [6]. - Currently, 143 out of 194 WHO member countries have included HPV vaccines in their national immunization plans, indicating a global trend towards increased vaccination [6]. - With the supply of HPV vaccines becoming sufficient and prices decreasing, the timing for including HPV vaccines in the national immunization program in China is considered ripe [7]. - The minimum price for HPV vaccines has dropped to 27.5 yuan per dose, significantly lower than initial prices, making it more accessible [7]. - If included in the national immunization program, HPV vaccines would likely see increased sales despite lower profit margins compared to local immunization programs [7].

Group 1 - The Chinese government plans to include HPV vaccination services for eligible girls in the national immunization program to enhance women's health protection [1][2] - The first domestic nine-valent HPV vaccine was approved by the National Medical Products Administration in June, breaking the long-standing market monopoly of foreign products [2] - The WHO has set a target for 90% of girls to complete HPV vaccination by the age of 15 by 2030 as part of its strategy to accelerate the elimination of cervical cancer [2][3] Group 2 - The "Action Plan" aims to pilot HPV vaccination services for eligible girls by 2025, with cervical cancer screening rates for eligible women reaching 50% and treatment rates for cervical cancer and precancerous lesions at 90% [3][4] - By 2030, the plan targets a 70% cervical cancer screening rate and maintaining a 90% treatment rate for patients [3] - The government has initiated free vaccination programs for eligible girls in 17 provinces and regions, including Hainan, Fujian, and Guangdong [4][5]

Core Viewpoint - The article discusses the significant expansion of the national immunization program in China, with the inclusion of the HPV vaccine aimed at protecting women's health, particularly targeting school-aged girls [3][4]. Group 1: HPV Vaccine Inclusion - The HPV vaccine will be added to the national immunization program, focusing on the bivalent vaccine for school-aged girls [3]. - This marks a shift from a child-centric vaccination approach to a "lifecycle vaccination" strategy [3]. - The bivalent vaccine primarily targets HPV types 16 and 18, which account for 70%-80% of cervical cancer cases [3][4]. Group 2: Cervical Cancer Statistics - Cervical cancer is the second most common malignancy among women globally, with China accounting for 23% of cases and 16% of deaths worldwide [4]. - Nearly all cervical cancer cases (99.7%) are linked to HPV infection, which can lead to cervical cancer if persistent [4]. Group 3: Government Initiatives - The Chinese government has been promoting free HPV vaccination for eligible girls, with 18 provinces and several cities already implementing this initiative [5][6]. - Approximately 60% of eligible girls in China are now covered by the free vaccination policy [5]. Group 4: Vaccine Accessibility and Cost - The production and research capabilities for HPV vaccines in China have significantly improved since 2021, with two domestic bivalent vaccines approved for use [7]. - The price of the HPV vaccine has dropped dramatically, with the lowest bid now at 27.5 yuan per dose, less than one-tenth of the initial price [7]. Group 5: Comprehensive Prevention Strategy - The successful inclusion of the HPV vaccine in the national immunization program is expected to enhance the integration of primary and secondary prevention strategies for cervical cancer [8]. - A comprehensive prevention strategy may include vaccination, screening, and early diagnosis and treatment [8]. Group 6: Future Directions - The national health authorities are preparing a five-year plan to narrow the gap between domestic and international immunization programs, considering the addition of new vaccines and optimizing existing vaccination schedules [9]. - The exploration of vaccine exit strategies for those not suitable for universal vaccination is also on the agenda [9].

Core Viewpoint - The Chinese government has included the HPV vaccine in the national immunization program, allowing eligible girls to receive the vaccine for free starting this year [2][3]. Group 1: National Immunization Program Expansion - This marks the first expansion of the national immunization program in 18 years, with the HPV vaccine being prioritized for inclusion [2]. - Since 2007, the immunization program has maintained a structure of "fourteen vaccines for fifteen diseases," with no substantial additions in vaccine types over the years [2]. - As of 2024, 147 out of 194 WHO member countries have included the HPV vaccine in their immunization programs [2]. Group 2: HPV Vaccine and Cervical Cancer - HPV is a common virus primarily transmitted through sexual contact, with persistent infection of 14 high-risk HPV types being the main cause of cervical cancer [2]. - Vaccination can prevent at least 70% of cervical cancer cases, which is critical given the rising incidence and mortality rates of cervical cancer in China [2]. - In 2022, approximately 150,000 new cervical cancer cases and about 56,000 deaths were reported in China [2]. Group 3: Local Government Initiatives - Several local governments have already initiated free HPV vaccination programs for eligible girls, with Guangdong province being one of the earliest adopters since 2022 [3][4]. - The program in Guangdong requires eligible girls to meet specific criteria, including being under 14 years old and having no prior HPV vaccination [4]. - Over 17 provinces in China have implemented similar free vaccination projects, although the distribution of these programs is uneven, with fewer initiatives in central and northeastern regions compared to eastern and southern areas [4]. Group 4: Market Impact - Following the announcement of the HPV vaccine's inclusion in the immunization program, stock prices of several HPV vaccine manufacturers rose [5]. - WanTai BioPharmaceuticals saw a 2.52% increase in stock price, while Watson Bio and Zhifei Biological also experienced stock price increases of 1.22% and 1.71%, respectively [5].

Group 1 - The Chinese government has expanded its national immunization program to include the HPV vaccine, allowing eligible individuals to receive it for free starting this year [2] - The inclusion of the HPV vaccine in the national immunization program is aimed at protecting women's health and is a significant change after 18 years of maintaining the previous immunization framework [2][3] - The HPV vaccine is known to prevent at least 70% of cervical cancer cases, which is crucial given the rising incidence and mortality rates of cervical cancer in China [2][3] Group 2 - Over 17 provinces in China have already implemented free HPV vaccination programs for eligible girls, with most following a model similar to that of Guangdong Province [4][5] - The distribution of these vaccination programs is uneven, with fewer initiatives in central, western, and northeastern regions compared to eastern and southern regions [5] - Following the announcement of the HPV vaccine's inclusion in the immunization program, stock prices of several HPV vaccine companies rose, indicating positive market sentiment [5]

Core Viewpoint - The National Immunization Program in China will include the HPV vaccine this year, marking a significant expansion after 17 years, aimed at protecting women's health [1][2]. Group 1: HPV Vaccine Inclusion - The HPV vaccine will be a bivalent type, primarily targeting school-aged girls, indicating a shift from childhood vaccination to a life-cycle approach [1]. - HPV types 16 and 18, which are responsible for 70%-80% of cervical cancer cases, will be the focus of the bivalent vaccine [1]. - Cervical cancer is the second leading cause of cancer-related deaths among women globally, with China accounting for 23% of cervical cancer cases and 16% of deaths worldwide [1][2]. Group 2: Government Initiatives - The Chinese government has been promoting free HPV vaccination for eligible girls, with 18 provinces and several cities already including it in public service projects, covering approximately 60% of eligible girls [2][3]. - The World Health Organization recommends that member countries include HPV vaccination in their national immunization programs, targeting girls aged 9 to 14 [2]. Group 3: Vaccine Supply and Awareness - The widespread promotion of HPV vaccination has increased public awareness and willingness to vaccinate, with 82% of surveyed individuals expressing a desire to vaccinate their daughters [3]. - The national immunization information system has achieved full coverage, enabling dynamic monitoring of HPV vaccination status [3]. Group 4: Production and Pricing - Since 2021, domestic production and research capabilities for HPV vaccines have significantly improved, with two bivalent vaccines approved and widely used [4]. - The price of the bivalent HPV vaccine has dropped significantly due to centralized procurement, with the lowest bid now at 27.5 yuan per dose, less than one-tenth of the initial price [4]. Group 5: Future Directions - The inclusion of the HPV vaccine in the national immunization program is expected to integrate with cervical cancer screening, forming a comprehensive prevention strategy [5]. - The National Health Commission is preparing a five-year plan to gradually align China's immunization program with international standards, including the addition of new vaccines and optimization of existing vaccination schedules [5].

Core Viewpoint - The inclusion of the HPV vaccine in the national immunization program marks a significant expansion, prioritizing coverage for eligible girls and transitioning the program towards a "lifecycle vaccination" approach [1][5]. Group 1: HPV Vaccine Inclusion and Impact - The HPV vaccine will be a bivalent type, primarily targeting girls of appropriate age, and is expected to be added to the national immunization program within the year [1]. - Cervical cancer is a leading cause of cancer-related deaths among women globally, with China accounting for 23% of cases and 16% of deaths worldwide [2]. - The World Health Organization recommends that member countries include HPV vaccination in their national immunization programs, aiming for 90% of girls to be vaccinated by age 15 [2]. Group 2: Current Vaccination Efforts and Accessibility - As of August, 18 provinces and several cities in China have included HPV vaccination in government initiatives, providing free vaccinations to approximately 60% of eligible girls [3]. - Public awareness and willingness to vaccinate have increased, with 82% of surveyed individuals expressing a desire to vaccinate their daughters against HPV [3]. - The national immunization information system has been fully established, enabling dynamic monitoring of HPV vaccination status [3]. Group 3: Vaccine Development and Cost Reduction - The production and research capabilities for HPV vaccines in China have significantly improved, with two bivalent vaccines approved and widely used [4]. - The price of the bivalent HPV vaccine has decreased dramatically due to provincial centralized procurement, with the lowest bid price now at 27.5 yuan per dose, less than one-tenth of the initial price [4]. Group 4: Future Directions and Strategies - The successful inclusion of the HPV vaccine is expected to enhance the integration of primary and secondary prevention strategies for cervical cancer [5]. - A comprehensive prevention strategy combining vaccination, screening, and early diagnosis is being developed [6]. - Future plans include expanding the types of vaccines in the national immunization program and optimizing existing vaccination protocols based on epidemiological trends and vaccine characteristics [6].

Group 1 - The Chinese government will introduce HPV vaccination services for eligible girls and include the HPV vaccine in the national immunization program, aiming to protect women's health [1][2] - China has a high burden of cervical cancer, with approximately 150,000 new cases and 56,000 deaths reported in 2022, accounting for 23% of global cases, and the incidence rate is rising, particularly among younger populations [1] - The inclusion of the HPV vaccine in the national immunization program is expected to maximize public health benefits and provide free vaccination opportunities for the most vulnerable populations [1][2] Group 2 - Experts have been advocating for the HPV vaccine to be included in the national immunization program to ensure equitable access to vaccination services across different socio-economic conditions [2] - The announcement marks a significant update to China's national immunization program, which has not expanded its vaccine offerings since 2007, and represents the first inclusion of a vaccine targeting a non-communicable disease [2] - This initiative is seen as an important exploration for the public health system, potentially paving the way for a comprehensive immunization program that spans the entire lifecycle [2]

Core Points - The National Immunization Program Expert Advisory Committee has been officially disclosed for the first time since its establishment in 2017, consisting of 30 experts from various fields [1][2] - The committee's role is to ensure independent decision-making based on scientific evidence regarding vaccine safety and efficacy, balancing fiscal and supply-demand considerations [1][2] - The new committee includes an increase of 2 members compared to the previous one, with Wang Junzhi as the chairperson, who has significant experience in vaccine research [2][4] Group 1 - The committee's members come from diverse fields such as epidemiology, microbiology, clinical medicine, health policy, and immunology [2][6] - The committee has previously approved and rejected various vaccination programs based on evidence, indicating a systematic decision-making process [1][2] - The new committee aims to enhance transparency, as this is the first time the member list and working regulations have been publicly shared [2][6] Group 2 - The committee's establishment is seen as a potential opportunity to update the national immunization program, which has not included new vaccines for several years [6][9] - There is a discussion on adjusting the funding model for the immunization program to reduce reliance on government finances, especially in light of declining birth rates [6] - The WHO recommends 10 vaccines for national immunization programs, of which China has not included four, highlighting a gap in vaccine coverage compared to developed countries [7][8]

Core Viewpoint - The transparency and scientific basis of China's immunization policy are expected to improve with the recent adjustments to the National Immunization Planning Expert Advisory Committee, which has expanded its membership and publicly disclosed its members for the first time since its establishment in 2017 [3][4]. Group 1: Expert Committee Adjustments - The National Immunization Planning Expert Advisory Committee has been expanded from 27 to 30 members, with a diverse range of experts from fields such as epidemiology, clinical medicine, and immunology [3][5]. - The new committee's term remains three years, and the updated regulations emphasize that committee members must not have direct interests with vaccine license holders to ensure decision-making independence [4][6]. Group 2: Committee's Role and Responsibilities - The core function of the committee is to provide evidence-based recommendations on vaccine usage and immunization strategies, including the introduction and adjustment of vaccines, immunization strategy optimization, and cost-effectiveness evaluations [5][6]. - The inclusion of experts from the fiscal and taxation fields in the new committee is significant, as it relates to health equity and public financial expenditure [5]. Group 3: Expert Profiles - The committee is chaired by Wang Junzhi, an academician with extensive experience in vaccine regulation and bio-products [6]. - Notable members include academicians Gao Fu and Xia Ning Shao, who have significant contributions to vaccine development and public health [6]. Group 4: Future Recommendations - Public health scholars suggest that the committee should adopt international best practices by establishing a regular information release system to enhance transparency and reduce vaccine hesitancy, ultimately improving national immunization coverage [7].